Loading cancer entity…
Loading cancer entity…
Clinical trials
62 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001465 | Study of the Disease Process of Lymphangioleiomyomatosis | recruiting | — | 2,000 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | active not recruiting | Phase 4 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 |
| clinicaltrials |
| NCT01484236 | National Lymphangioleiomyomatosis Registry, France(RE-LAM-CE) | recruiting | — | 200 | Vincent COTTINOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01799538 | Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | recruiting | Phase 1 / Phase 2 | 100 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05676099 | TSC Biosample Repository and Natural History Database | recruiting | — | 5,000 | National Tuberous Sclerosis AssociationOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06453642 | Evaluation of a Simple-Prep Controlled Embolic(GPX) | active not recruiting | N/A | 114 | Fluidx Medical Technology, Inc.INDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT03967834 | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group(MIRAS) | recruiting | N/A | 400 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06160310 | Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) | recruiting | — | 300 | David M. RitterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05467397 | Feasibility of [11C]Acetate-PET in LAM and TSC | active not recruiting | Phase 1 / Phase 2 | 7 | Brigham and Women's HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06889168 | Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)(LAMP-2) | recruiting | Phase 1 | 20 | Columbia UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07304856 | Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex | recruiting | — | 80 | University of MilanOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT02432560 | Safety and Durability of Sirolimus for Treatment of LAM(MIDAS) | recruiting | — | 600 | University of CincinnatiOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03150914 | Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial(MILED) | active not recruiting | Phase 3 | 60 | University of CincinnatiOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05727852 | Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases | enrolling by invitation | — | 400 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials